Tfelt-Hansen Peer
Danish Headache Centre,University of Copenhagen, Department of Neurology, Glostrup Hospital, Glostrup, Denmark.
Curr Clin Pharmacol. 2012 Feb 1;7(1):66-72. doi: 10.2174/157488412799218770.
Migraine is a common disorder with a female prevalence of 17% and a male prevalence of 9%. Migraine is most often disabling and the patients need treatment of the attacks. The introduction of triptans has been a revolution for many migraine patients but only a minority of patients use these specific drugs. The pharmacokinetics and efficacy and tolerability of triptans are reviewed. The triptans can most likely with advantage be combined with NSAIDs and prokinetic drugs. Among future drugs, CGRP receptor antagonists are the most promising. These drugs have shown excellent tolerability with no more adverse events than placebo, but only one quarter of migraine patients have been pain-free after 2 hours in phase III studies. The development of current CGRP antagonists has been stopped.
偏头痛是一种常见疾病，女性患病率为17%，男性患病率为9%。偏头痛常常使人丧失能力，患者需要对发作进行治疗。曲坦类药物的引入对许多偏头痛患者来说是一场革命，但只有少数患者使用这些特定药物。本文综述了曲坦类药物的药代动力学、疗效和耐受性。曲坦类药物很可能与非甾体抗炎药和促动力药物联合使用会更有益。在未来的药物中，降钙素基因相关肽（CGRP）受体拮抗剂最有前景。这些药物已显示出极佳的耐受性，不良事件不比安慰剂多，但在III期研究中，只有四分之一的偏头痛患者在2小时后疼痛消失。目前CGRP拮抗剂的研发已停止。
